Cargando…

Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report

A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised c...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirufo, Maria Maddalena, Raggiunti, Martina, Magnanimi, Lina Maria, Ginaldi, Lia, De Martinis, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539285/
https://www.ncbi.nlm.nih.gov/pubmed/34696186
http://dx.doi.org/10.3390/vaccines9101078
_version_ 1784588709986828288
author Sirufo, Maria Maddalena
Raggiunti, Martina
Magnanimi, Lina Maria
Ginaldi, Lia
De Martinis, Massimo
author_facet Sirufo, Maria Maddalena
Raggiunti, Martina
Magnanimi, Lina Maria
Ginaldi, Lia
De Martinis, Massimo
author_sort Sirufo, Maria Maddalena
collection PubMed
description A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial.
format Online
Article
Text
id pubmed-8539285
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85392852021-10-24 Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report Sirufo, Maria Maddalena Raggiunti, Martina Magnanimi, Lina Maria Ginaldi, Lia De Martinis, Massimo Vaccines (Basel) Case Report A 76 year-old female came to our observation one week after the vaccination with ChAdOx1 nCoV-19 AZD1222 for the onset of purpuric rash on her gluteal and legs regions associated with coxalgia and episodes of macrohaematuria. Henoch-Schönlein purpura (HSP) was diagnosed on the basis of the revised criteria developed by the European League Against Rheumatism, the Paediatric Rheumatology International Trials Organization, and the Paediatric Rheumatology European Society (EULAR/PRINTO/PRES). HSP is a common IgA-mediated small vessel vasculitis, typical of childhood, that affects several systems and is characterized by a tetrad of dermatological, abdominal, joint, and renal manifestations. The Etiology of HSP is not completely understood, but it was observed following upper respiratory tract infections, medications, vaccinations, and malignancies. HSP has previously been reported following immunization with various vaccines, mostly within 12 weeks post, suggesting a possible correlation. To our knowledge, this is the first report of the possible association between COVID-19 ChAdOx1 nCoV-19 AZD1222 and the onset of HSP in a previously healthy woman. No similar cases were reported amongst 23.848 participants in the ChAdOx1 nCoV-19 AZD1222 trial. MDPI 2021-09-25 /pmc/articles/PMC8539285/ /pubmed/34696186 http://dx.doi.org/10.3390/vaccines9101078 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Sirufo, Maria Maddalena
Raggiunti, Martina
Magnanimi, Lina Maria
Ginaldi, Lia
De Martinis, Massimo
Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title_full Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title_fullStr Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title_full_unstemmed Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title_short Henoch-Schönlein Purpura Following the First Dose of COVID-19 Viral Vector Vaccine: A Case Report
title_sort henoch-schönlein purpura following the first dose of covid-19 viral vector vaccine: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539285/
https://www.ncbi.nlm.nih.gov/pubmed/34696186
http://dx.doi.org/10.3390/vaccines9101078
work_keys_str_mv AT sirufomariamaddalena henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport
AT raggiuntimartina henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport
AT magnanimilinamaria henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport
AT ginaldilia henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport
AT demartinismassimo henochschonleinpurpurafollowingthefirstdoseofcovid19viralvectorvaccineacasereport